

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2021
FOR
AMMF
(THE ALAN MOREMENT MEMORIAL FUND)**

Haslers
Chartered Accountants
Old Station Road
Loughton
Essex
IG10 4PL

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2021

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 to 18
Detailed Statement of Financial Activities	19 to 20

**AMMF
(THE ALAN MOREMENT MEMORIAL FUND)**

**REFERENCE AND ADMINISTRATIVE DETAILS
FOR THE YEAR ENDED 31 JANUARY 2021**

TRUSTEES	Mr T P Morement Mr N Corrigan Chairman Mr H Corrigan Mrs G C Meares Corrigan
PRINCIPAL ADDRESS	Enterprise House Bassingbourn Road Stansted Essex CM24 1QW
REGISTERED CHARITY NUMBER	1091915
INDEPENDENT EXAMINER	Haslers Chartered Accountants Old Station Road Loughton Essex IG10 4PL

**AMMF
(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2021**

The trustees present their report with the financial statements of the charity for the year ended 31 January 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

When AMMF was founded in the UK and registered with the Charity Commission in 2002, it was the world's first charity dedicated solely to cholangiocarcinoma (bile duct cancer). It remains the UK's and Europe's only dedicated cholangiocarcinoma (CCA) charity.

AMMF is wholly committed nationally and internationally to tackling this devastating cancer on all fronts and, ultimately, to help find a cure, through:

- **Support** - Providing information to individuals or groups to support a patient or loved one along their journey
- **Empowerment** - Empowering patients and their loved ones to advocate for themselves, seek better care, new treatment options and second opinions
- **Access** - Advocating for patients to ensure they have access to the latest treatment options and a minimum standard of care appropriate to them
- **Awareness** - Raising awareness of cholangiocarcinoma to support earlier diagnosis, fair and equal access to treatments, including new treatment approaches
- **Research** - Encouraging and supporting continued research into causes, diagnostics, and new treatment options for those with cholangiocarcinoma
- **Policy** - Ensuring health care policies reflect the needs of those with cholangiocarcinoma

Cholangiocarcinoma is under-represented and under-funded across all areas, including policy, services, and research. It is a poorly understood and under researched disease which is increasing in incidence not only in the UK but throughout the world. Lack of awareness and the difficulties of achieving clear and accurate diagnosis, mean that most are at an advanced stage and inoperable at time of diagnosis.

Surgery remains the only potentially curative treatment - there is palliative chemotherapy and there are some trials - but a diagnosis of inoperable cholangiocarcinoma is invariably fatal, and this is a situation that has not changed in decades. AMMF is committed to working to change this scenario and strongly believes international collaboration is the way forward.

Resolute in bringing about improvement for the cholangiocarcinoma patient, AMMF continues to work closely with patients and their carers, clinicians, healthcare professionals, researchers, and policy makers, as well as actively collaborating globally.

During the year 2020, despite the limitations brought about by the COVID-19 pandemic, the charity continued its advocacy work, especially in helping cholangiocarcinoma patients navigate their way to continue essential treatments wherever possible.

AMMF's MISSION

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2021

Raising Awareness

The Global Cholangiocarcinoma Alliance

Building on the foundation of three successful annual World Cholangiocarcinoma Days, an AMMF-instigated initiative, The Global Cholangiocarcinoma Alliance (GCA) was established at AMMF's international workshop held in London in 2018. This venture aims to provide a united voice through international collaboration, to seek further ways to drive awareness and education globally, and to address the current challenges in cholangiocarcinoma.

Since that time, and throughout 2020, AMMF continued to work with the agency Scientific Education Support (SES), acting as the not-for-profit partner as the work towards formalising a governance structure and the formation of an international steering committee was completed.

The newly formed steering committee provided direction and content recommendations for all aspects of the Global Cholangiocarcinoma Alliance during 2020, and the agency SES partnered with them in building a comprehensive portfolio of initiatives, designed to provide the global cholangiocarcinoma community with a platform on which to build links and exchange knowledge in order to raise the global awareness of CCA and improve the education of both healthcare professionals and patients. The projects will begin in 2021, and continue throughout the year, with SES ensuring they are delivered in accordance with agreed timelines.

Led by SES, World Cholangiocarcinoma Day 2020 was held on 12 February, with a social media focused campaign themed on sharing knowledge through global collaboration. The day was well-supported globally across social media, substantially raising the profile of the Global CCA Alliance. And at the end of 2020, plans were well underway for the 2021 World CCA Day.

Due to the COVID-19 pandemic, touchpoint GCA meetings planned to be held at major conferences throughout the year had to be cancelled, but where possible these were rescheduled to be held virtually. This enabled the work of the Alliance to continue.

OBJECTIVES AND ACTIVITIES

Raising Awareness

AMMF's Cholangiocarcinoma Conference 2020

Planning for AMMF's annual Cholangiocarcinoma Conference in May 2020 was well underway when the first compulsory lockdown of the COVID-19 pandemic began and, as the severity of the pandemic became clear, this event had to be postponed.

Later in the year AMMF held a smaller virtual event for patients and carers, to share with them some of the information they had missed from AMMF's main conference, but the charity was not able to organise main part of the conference as a virtual event during 2020.

**AMMF
(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2021**

Patient information day, October 2020

AMMF's virtual Cholangiocarcinoma (CCA) Information Day, especially for patients and carers, took place on Thursday, 29 October 2020.

This was attended not only by patients and their loved ones, but also by clinical nurse specialists who wanted to learn more about cholangiocarcinoma, and by industry members, whose companies are working hard to develop drugs and improved treatments for those with CCA.

The day's agenda covered three important topics - an overview of cholangiocarcinoma, an update on treatments and trials, and a discussion on nutrition and diet for those with cholangiocarcinoma - and we were very fortunate to have with us expert speakers - Professor Shahid A Khan, Professor Juan Valle, and Ms Glenda O'Connor - each of whom are dedicated to helping improve the situation for all those now and in the future, with cholangiocarcinoma.

Cholangiocarcinoma Data Analysis Project

Lack of robust data for cholangiocarcinoma has long been seen by AMMF as a major reason why there is so little awareness of this cancer, and so little progress. Robust data are essential to drive policy, to encourage research funding, to stimulate interest, and so much more.

Working towards rectifying this, Helen Morement, CEO of AMMF, along with Professor Shahid A Khan, a hepatologist, and Professor Mireille Toledano, an epidemiologist, both of Imperial College London, prepared a cholangiocarcinoma data project proposal which was submitted to and accepted by the National Cancer Registration and Analysis Service (NCRAS) and PHE (Public Health England).

In 2019, AMMF entered into a partnership with NCRAS and PHE, employing a data analyst to be embedded with NCRAS to work on the first part of the project to show the incidence and mortality, and survival, including age/gender breakdown. A poster, showing early results of this work, had been presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona in the summer of 2019.

When AMMF's analyst left in early 2020, the first part of the project was substantially completed, and it had been hoped that this work, "Incidence, mortality and survival for people diagnosed in England with Cholangiocarcinoma between 2001-2017", would be ready for publication during 2020. However, the COVID-19 pandemic and the lockdowns delayed this, and we are now looking at publication towards the end of 2021.

The second part of the project, "Routes to diagnosis and treatment of cholangiocarcinoma in England from 2006 to 2017: Are there any inequalities?", was developed to investigate treatments received, regional variation, and more. This was submitted to and approved by NCRAS/PHE and AMMF then commissioned the organisation HDI (Health Data Insight) to carry out this work.

A poster highlighting further outcomes of the data project and entitled, "Cholangiocarcinoma in England - a national study examining changes in incidence, diagnostic routes and overall survival", was accepted for presentation at the EASL (European Association for the Study of the Liver) international Congress in London in November 2020.

It is hoped both parts of the project will reach completion ready for publication during 2021, and AMMF believes the final outcome of the CCA data project will answer many of the questions there currently are relating to the epidemiological trends of cholangiocarcinoma and will help in the charity's work towards better recognition for this cancer and an improved situation for all those diagnosed with it.

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2021

OBJECTIVES AND ACTIVITIES

Public benefit

In forming the charity's objectives and planning the activities, the trustees have considered the Charity Commission's guidance in respect of public benefit.

ACHIEVEMENT AND PERFORMANCE

Supporting Research

AMMF remains committed to supporting research into cholangiocarcinoma.

During the year 2020 new grant awards were agreed as follows:

University of Nottingham - £28,750.29 was awarded in June 2020, to be given in two instalments, to fund consumables and technical support for Dr Isioma Egbuniwe's work on "Interleukin 17 (IL-17) in Tumour Lymphangiogenesis in Cholangiocarcinoma".

University of Liverpool - £25,000 awarded in June 2020, to be given in one instalment, to fund the work of Mr Marc Quinn, "Interrogating tumour-mediated immunosuppression in perihilar cholangiocarcinoma".

During 2020 the following payments were made re new and existing awards:

University of Edinburgh - £34,325 was paid in July 2020 in respect of the 2nd instalment of a grant of £102,515 awarded in September 2017 to fund a 3-year PhD scholarship in Dr Luke Boulter's lab, working on the project, "Understanding the role of seed cells and epithelial co-option in cholangiocarcinoma".

University of Oxford - £24,255.89 (3rd instalment) was paid in December 2020 in respect of an award of £90,000 agreed in May 2018 to be given over three years to fund Dr Shijie Cai's work re an integrated proteomic and metabolomics approach to investigate the role of ubiquitin-specific protease 22 and its responsive pathways in cholangiocarcinoma.

University of Nottingham - £19,262 was paid in one instalment in December 2020 in respect of an award of this amount agreed to fund one year of Dr Sheela Jayaraman's work on new strategies for the inhibition of cholangiocarcinoma tumour growth.

***Note:** This award was originally made for Dr Jayaraman's work at the University of Birmingham, but she requested that it be moved with her to the University of Nottingham when she accepted a post there in October 2020. The research work remained the same, so AMMF's board of trustees agreed to this 05.10.2020.*

University of Nottingham - £16,169.00 was paid in December 2020, in respect of the first instalment of an award of £28,750.29 agreed in June 2020, to be given in two instalments, to fund consumables and technical support for Dr Isioma Egbuniwe's work on "Interleukin 17 (IL-17) in Tumour Lymphangiogenesis in Cholangiocarcinoma".

University of Leeds - a total of £12,470.58 was paid during the year against invoiced actual consumable spend (January 2020: £2,937.88, March 2020: £8,399.87, January 2021: £1,132.83) in respect of an award of £45,000 which was agreed in July 2018 to be given over three years, to fund consumables required in the work of Dr Stephen Griffin on virus-driven intrahepatic cholangiocarcinoma.

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2021

ACHIEVEMENT AND PERFORMANCE

AMMF's External Activities

The charity is recognized widely, nationally and internationally, both amongst the general public and within medical circles, for its work in the field of cholangiocarcinoma.

As a member of the NCRI's (National Cancer Research Institute) Upper Gastrointestinal Hepatobiliary clinical trials group, and the IBTCC (International Biliary Tract Cancers Collaborators) group AMMF has made valuable contacts with those at the forefront of cholangiocarcinoma research and treatments throughout the UK and internationally.

COVID-19

During January and February 2020, it became apparent that there was a health crisis developing. The incredibly infectious and dangerous COVID-19 virus was building in intensity. At AMMF, external visitors were cancelled, as was attendance at external meetings. During those weeks, all staff were instructed to ensure that their AMMF-supplied computer and other equipment they already had in place for occasional working from home, was working well should we need to resort to remote working for a period of time, and contingency plans were put in place to ensure secure sharing of digital files during any such remote working.

With heightening concerns over the advance of the virus, on 18 March AMMF's board of trustees instructed AMMF's CEO and staff to begin working remotely until further notice, and on 23rd March 2020, Prime Minister, Boris Johnson, instigated the first nationwide full lockdown.

Working remotely continued throughout the year, with team meetings take place daily via Zoom, and each member of staff continuing to work their normal hours.

All overseas and UK conferences and face to face meetings were cancelled, replaced where possible by virtual events. During the year, AMMF attended and presented at a number of these virtual events, including the UK Oncology Forum conference, ESMO World Congress (virtual) with Helen Morement, AMMF's CEO, speaking at and co-chairing the Incyte symposium, and she was also invited to become part of Incyte's CCA Multi-Disciplinary Team Educational Campaign Advisory Board.

During the year, the charity was approached by NICE to put forward a submission for the approval of a new targeted therapy for cholangiocarcinoma, and the CEO was invited to sit on a US FDA (Food and Drug Administration) committee exploring improved eligibility rules for clinical trials.

AMMF is a member of the European Network for the Study of Cholangiocarcinoma (ENS-CCA), an association of research groups from twelve European countries actively working on basic, translational, and clinical research into cholangiocarcinoma, and the charity's CEO is chair of the ENS-CCA Patient Advocacy Committee.

AMMF continues to be an active member of Cancer52, the alliance of rare and less common cancer organisations, which provides "the common voice for less common cancers". AMMF's CEO, Helen Morement was appointed a board director of Cancer52 in 2014, and has continued in this role since then, during 2020 attending board meetings and general meetings virtually. Through this membership, the charity is enabled to have a presence and a voice within every national cancer initiative. AMMF's trustees see this role as providing an opportunity to work more closely with this influential organisation, and in identifying priority challenges and opportunities for all those in the rare and less common cancers community.

**AMMF
(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2021**

ACHIEVEMENT AND PERFORMANCE

Information for those who need it, and providing patient information during the pandemic:

As the pandemic progressed during 2020, AMMF's CEO attended weekly virtual NHS cancer charity briefing meetings in order to provide the clearest possible information to those who approached the charity for help. AMMF's Medical and Clinical Advisors were also contacted on a regular basis, to gain an overview of the difficulties that they were experiencing in being able to care for their CCA patients, and for advice on how best to handle the patient queries the charity was receiving.

The Patient Support area of AMMF's website was updated to include a section for COVID-19 advice for CCA patients, with links to appropriate NHS and Government information, and this was updated on a regular basis. Helpful information was also disseminated across AMMF's social media channels whenever possible.

The general areas of AMMF's website continue to be updated regularly, providing information on all aspects of cholangiocarcinoma, including treatments and specialists, and on the advances being made. There is an area specifically for patients and their families, including a discussion forum, 'Our CC Family' and 'Helpful Links', and importantly, there is a comprehensive list of the clinical trials that are available and recruiting in the UK, which is proving a valuable resource to medics and patients.

The charity's active social media platforms kept supporters up to date with information of importance and relevance to them throughout the year. AMMF's Facebook page now has over 5,000 followers, and the following on both Twitter and Instagram continues to grow.

The requirement from individual patients and family members for specific information regarding specialist consultants and treatments continues to increase. With the wider awareness of the charity, increasing incidence and growing recognition of cholangiocarcinoma, it is anticipated this area of work will continue to increase.

In summary

2020 has been a very difficult year but, despite the unforeseen problems, the charity has continued to expand its reach and influence nationally and internationally. AMMF is the UK's only cholangiocarcinoma charity and, although by its nature will remain a niche charity, is now firmly established in the UK, Europe and beyond.

As we enter 2021, we look forward with some caution because of the ongoing problems of the pandemic but, with the help of our loyal fundraisers and supporters who have been steadfastly with us throughout this year, AMMF remains fully committed to working towards a far better future for those diagnosed with cholangiocarcinoma.

FINANCIAL REVIEW

Financial review and reserves policy

The charity has continued to strengthen its financial position during the year.

The charity ensures that sufficient reserves are retained in an appropriate form to fund its current obligations.

Where specific research projects have been secured, the trustees designate sufficient unrestricted reserves to cover the expected future grants payable over the term of the research project.

**AMMF
(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2021**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Approved by order of the board of trustees on 12 November, 2021 and signed on its behalf by:



.....
Mr N Corrigan - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
AMMF
(THE ALAN MOREMENT MEMORIAL FUND)**

Independent examiner's report to the trustees of AMMF (The Alan Morement Memorial Fund)

I report to the charity trustees on my examination of the accounts of AMMF (The Alan Morement Memorial Fund) (the Trust) for the year ended 31 January 2021.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ACCA which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Paul Thain BA (Hons) FCCA
ACCA
Haslers
Chartered Accountants
Old Station Road
Loughton
Essex
IG10 4PL

Date: 22 November 2021

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 JANUARY 2021

				2021	2020
	Notes	Unrestricted general fund £	Unrestricted research projects £	Restricted research funds £	Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	421,717	-	17,688	439,405
Other trading activities	3	5,108	-	-	5,108
Investment income	4	1,146	-	-	1,146
Other income		<u>10,000</u>	<u>-</u>	<u>-</u>	<u>10,000</u>
Total		437,971	-	17,688	455,659
EXPENDITURE ON					
Raising funds	5	138,917	-	-	138,917
Charitable activities	6				
Grants Payable		<u>260,035</u>	<u>-</u>	<u>-</u>	<u>260,035</u>
Total		<u>398,952</u>	<u>-</u>	<u>-</u>	<u>488,050</u>
NET INCOME/(EXPENDITURE)		39,019	-	17,688	56,707
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>360,065</u>	<u>-</u>	<u>3,432</u>	<u>363,497</u>
TOTAL FUNDS CARRIED FORWARD		399,084	-	21,120	420,204

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

BALANCE SHEET
31 JANUARY 2021

					2021	2020
	Notes	Unrestricted general fund £	Unrestricted research projects £	Restricted research funds £	Total funds £	Total funds £
FIXED ASSETS						
Tangible assets	11	857	-	-	857	2,003
CURRENT ASSETS						
Stocks	12	5,355	-	-	5,355	5,281
Prepayments and accrued income		10,816	-	-	10,816	6,724
Cash at bank and in hand		<u>386,816</u>	<u>-</u>	<u>21,120</u>	<u>407,936</u>	<u>355,737</u>
		402,987	-	21,120	424,107	367,742
CREDITORS						
Amounts falling due within one year	13	(4,760)	-	-	(4,760)	(6,248)
NET CURRENT ASSETS		<u>398,227</u>	<u>-</u>	<u>21,120</u>	<u>419,347</u>	<u>361,494</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>399,084</u>	<u>-</u>	<u>21,120</u>	<u>420,204</u>	<u>363,497</u>
NET ASSETS		<u>399,084</u>	<u>-</u>	<u>21,120</u>	<u>420,204</u>	<u>363,497</u>
FUNDS	15					
Unrestricted funds:						
Unrestricted general fund					399,084	360,065
Restricted funds:						
Restricted research funds					<u>21,120</u>	<u>3,432</u>
TOTAL FUNDS					<u>420,204</u>	<u>363,497</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 12 November, 2021 and were signed on its behalf by:



.....
Mr N Corrigan - Trustee

**AMMF
(THE ALAN MOREMENT MEMORIAL FUND)**

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2021**

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

The Alan Morement Memorial Fund is an unincorporated charity. The principal office is detailed on page 1 of the financial statements. The financial statements are presented in Sterling which is the functional currency of the charity. The financial statements comply with section 1A of FRS 102.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 33% on cost

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. Stock is recorded on a first in, first out basis.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. The trustees may at their discretion designate a portion of unrestricted funds for a particular purpose. Such designation is a means to set aside funds for that purpose and is not binding on the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2021

1. ACCOUNTING POLICIES - continued

Operating leases

Leases where substantially all the risks and rewards incidental to ownership are retained by the lessors are classified as operating leases. Payments made under operating leases are recognised in the Statement of Financial Activities on a straight-line basis over the period of the lease.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2. DONATIONS AND LEGACIES

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds
	£	£	£	£
Donations and fundraising	392,114	17,688	409,802	424,653
Gift aid	<u>29,603</u>	<u>-</u>	<u>29,603</u>	<u>29,466</u>
	<u>421,717</u>	<u>17,688</u>	<u>439,405</u>	<u>454,119</u>

3. OTHER TRADING ACTIVITIES

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds
	£	£	£	£
Shop income	<u>5,108</u>	<u>-</u>	<u>5,108</u>	<u>6,843</u>

4. INVESTMENT INCOME

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds
	£	£	£	£
Deposit account interest	<u>1,146</u>	<u>-</u>	<u>1,146</u>	<u>1,357</u>

5. RAISING FUNDS

Raising donations and legacies

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds
	£	£	£	£
Support costs	<u>131,431</u>	<u>-</u>	<u>131,431</u>	<u>240,554</u>

An analysis of support costs is shown in note 8 below.

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2021

5. RAISING FUNDS - continued

Other trading activities

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds
	£	£	£	£
Shop stock purchases	7,135	-	7,135	6,234
Fundraising	<u>351</u>	<u>-</u>	<u>351</u>	<u>454</u>
	<u>7,486</u>	<u>-</u>	<u>7,486</u>	<u>6,688</u>
Aggregate amounts	<u>138,917</u>	<u>-</u>	<u>138,917</u>	<u>247,242</u>

6. CHARITABLE ACTIVITIES COSTS

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds
	£	£	£	£
Research grants	<u>82,432</u>	<u>-</u>	<u>82,432</u>	<u>107,398</u>

7. GRANTS PAYABLE

	2021 £	2020 £
Grants Payable	<u>260,035</u>	<u>240,808</u>

All grants were paid to institutions.

The individual grant awards are detailed in the Trustees report.

8. SUPPORT COSTS

	Management £	Finance £	Totals £
Raising donations and legacies	<u>130,859</u>	<u>572</u>	<u>131,431</u>

Support costs, included in the above, are as follows:

	2021 Raising donations and legacies £	2020 Total activities £
Wages	64,546	91,000
Social security	1,282	4,913
Pensions	608	1,400
Equipment leasing	2,982	2,982
Operating lease - office rent & service charges	26,472	28,546
Rates and water	<u>1,634</u>	<u>1,595</u>
Carried forward	<u>97,524</u>	<u>130,436</u>

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2021

8. SUPPORT COSTS - continued

	2021 Raising donations and legacies £	2020 Total activities £
Brought forward	97,524	130,436
Insurance	529	481
Marketing and advertising	5,284	29,374
Telephone	3,162	3,156
Postage and stationery	3,984	6,129
Computer and website support	10,249	6,986
Travel	1,870	7,871
Subscriptions	1,230	1,207
Sundries	23	372
Training	50	80
Depreciation of computer equipment	1,146	1,144
Professional fees	2,934	2,126
Conference expenses	2,874	50,346
Bank charges	572	846
	<u>131,431</u>	<u>240,554</u>

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 January 2021 nor for the year ended 31 January 2020.

Trustees' expenses

No trustee expenses were incurred in the year to 31 January 2021 nor for the year to 31 January 2020.

10. STAFF COSTS

	2021 £	2020 £
Wages and salaries	64,546	91,000
Social security costs	1,282	4,913
Other pension costs	608	1,400
	<u>66,436</u>	<u>97,313</u>

The average monthly number of employees during the year was as follows:

	2021	2020
Management and administration	<u>3</u>	<u>4</u>

No employees received emoluments in excess of £60,000.

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2021

11. TANGIBLE FIXED ASSETS

	Computer equipment £
COST	
At 1 February 2020 and 31 January 2021	<u>10,305</u>
DEPRECIATION	
At 1 February 2020	8,302
Charge for year	<u>1,146</u>
At 31 January 2021	<u>9,448</u>
NET BOOK VALUE	
At 31 January 2021	<u>857</u>
At 31 January 2020	<u>2,003</u>

12. STOCKS

	2021 £	2020 £
Goods for resale	<u>5,355</u>	<u>5,281</u>

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021 £	2020 £
Taxation and social security	2,164	1,057
Other creditors	<u>2,596</u>	<u>5,191</u>
	<u>4,760</u>	<u>6,248</u>

14. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:

	2021 £	2020 £
Between one and five years	<u>15,546</u>	<u>18,528</u>

15. MOVEMENT IN FUNDS

	At 1/2/20 £	Net movement in funds £	At 31/1/21 £
Unrestricted funds			
Unrestricted general fund	360,065	39,019	399,084
Restricted funds			
Restricted research funds	3,432	17,688	21,120
TOTAL FUNDS	<u>363,497</u>	<u>56,707</u>	<u>420,204</u>

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2021

15. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
Unrestricted general fund	437,971	(398,952)	39,019
Restricted funds			
Restricted research funds	17,688	-	17,688
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>455,659</u>	<u>(398,952)</u>	<u>56,707</u>

Comparatives for movement in funds

	At 1/2/19 £	Net movement in funds £	At 31/1/20 £
Unrestricted funds			
Unrestricted general fund	388,719	(28,654)	360,065
Restricted funds			
Restricted research funds	509	2,923	3,432
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>389,228</u>	<u>(25,731)</u>	<u>363,497</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
Unrestricted general fund	449,396	(478,050)	(28,654)
Restricted funds			
Restricted research funds	12,923	(10,000)	2,923
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>462,319</u>	<u>(488,050)</u>	<u>(25,731)</u>

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2021

15. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/2/19 £	Net movement in funds £	At 31/1/21 £
Unrestricted funds			
Unrestricted general fund	388,719	10,365	399,084
Restricted funds			
Restricted research funds	509	20,611	21,120
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>389,228</u>	<u>30,976</u>	<u>420,204</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
Unrestricted general fund	887,367	(877,002)	10,365
Restricted funds			
Restricted research funds	30,611	(10,000)	20,611
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>917,978</u>	<u>(887,002)</u>	<u>30,976</u>

Restricted funds represent donations where the donor has requested that their donation be used for research purposes only. These donations are held within restricted funds until used in part or in whole to fund a cholangiocarcinoma research project which the charity has committed to supporting.

Designated funds represent amounts set aside at the Trustees' discretion, to fund future instalments of research projects which are to be undertaken over a number of years. Details of the individual research projects are explained in the Trustees' Report.

16. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 January 2021.

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 JANUARY 2021

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
INCOME AND ENDOWMENTS				
Donations and legacies				
Donations and fundraising	392,114	17,688	409,802	424,653
Gift aid	<u>29,603</u>	<u>-</u>	<u>29,603</u>	<u>29,466</u>
	421,717	17,688	439,405	454,119
Other trading activities				
Shop income	5,108	-	5,108	6,843
Investment income				
Deposit account interest	1,146	-	1,146	1,357
Other income				
Discretionary grant award	<u>10,000</u>	<u>-</u>	<u>10,000</u>	<u>-</u>
Total incoming resources	437,971	17,688	455,659	462,319
EXPENDITURE				
Other trading activities				
Shop stock purchases	7,135	-	7,135	6,234
Fundraising	<u>351</u>	<u>-</u>	<u>351</u>	<u>454</u>
	7,486	-	7,486	6,688
Charitable activities				
Grants to institutions	260,035	-	260,035	240,808
Support costs				
Management				
Wages	64,546	-	64,546	91,000
Social security	1,282	-	1,282	4,913
Pensions	608	-	608	1,400
Equipment leasing	2,982	-	2,982	2,982
Operating lease - office rent and service charges	26,472	-	26,472	28,546
Rates and water	1,634	-	1,634	1,595
Insurance	529	-	529	481
Marketing and advertising	5,284	-	5,284	29,374
Telephone	3,162	-	3,162	3,156
Postage and stationery	3,984	-	3,984	6,129
Computer and website support	10,249	-	10,249	6,986
Travel	1,870	-	1,870	7,871
Subscriptions	1,230	-	1,230	1,207
Sundries	23	-	23	372
Carried forward	123,855	-	123,855	186,012

AMMF
(THE ALAN MOREMENT MEMORIAL FUND)

DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 JANUARY 2021

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
Management				
Brought forward	123,855	-	123,855	186,012
Training	50	-	50	80
Depreciation of computer equipment	1,146	-	1,146	1,144
Professional fees	2,934	-	2,934	2,126
Conference expenses	<u>2,874</u>	<u>-</u>	<u>2,874</u>	<u>50,346</u>
	130,859	-	130,859	239,708
Finance				
Bank charges	<u>572</u>	<u>-</u>	<u>572</u>	<u>846</u>
Total resources expended	<u>398,952</u>	<u>-</u>	<u>398,952</u>	<u>488,050</u>
Net (expenditure)/income	<u>39,019</u>	<u>17,688</u>	<u>56,707</u>	<u>(25,731)</u>